|
02 Jul 2019 |
Bioinvent Receives Ind Approval For Phase I/IIa Trial of Anti-FcγRIIb Antibody
|
|
01 Jul 2019 |
CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer
|
|
01 Jul 2019 |
Menarini Ricerche Announces Publication of Pre-clinical Data of the First-in-class Antibody-drug Conjugate MEN1309/OBT076, Currently in Phase I Clinical Development
|
|
01 Jul 2019 |
Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union
|
|
01 Jul 2019 |
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
|
|
28 Jun 2019 |
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
|
|
28 Jun 2019 |
Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
|
|
28 Jun 2019 |
New report: Bispecific Antibodies for Immuno-Oncology & Other Diseases
|
|
27 Jun 2019 |
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
27 Jun 2019 |
IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
|
|
27 Jun 2019 |
NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)
|
|
27 Jun 2019 |
Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes
|
|
27 Jun 2019 |
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
|
|
25 Jun 2019 |
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States
|
|
24 Jun 2019 |
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
|
|
24 Jun 2019 |
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
|
|
24 Jun 2019 |
Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue® (Trastuzumab Biosimilar)
|
|
22 Jun 2019 |
ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
|
|
22 Jun 2019 |
European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
|
|
21 Jun 2019 |
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants
|
|
21 Jun 2019 |
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
|
|
19 Jun 2019 |
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
|
|
19 Jun 2019 |
Alligator Bioscience Submits Clinical Trial Application for ATOR-1017
|
|
19 Jun 2019 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
|
|
18 Jun 2019 |
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
|
